VivoSeq
Other

Pseudomyxoma Peritonei

13

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Pseudomyxoma Peritonei is an emerging landscape with 13 programs across 6 companies. The most active players are BeiGene, Novartis, Arbor Pharmaceuticals, Inc.. 2 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

0/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BeiGene logo

BeiGene

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 1A

Arbor Pharmaceuticals, Inc.

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2CSL Behring logo

CSL Behring

2 programs

Phase 3U

UroGen Pharma Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

10 of 12 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody18%Protein / enzyme18%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

7

clinical trials

Unknown status3 · 43%
Recruiting2 · 29%
Terminated1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei
Recruiting·OOslo University Hospital·Phase 1·NCT07341360·10 enrolled
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
Recruiting·CSL Behring logoCSL Behring·Phase 3·NCT06617897·90 enrolled
Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin
Active, not recruiting·MMercy Medical Center·Phase 2·NCT02387203·80 enrolled
A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis
Terminated·WWashington University School of Medicine·Phase 2·NCT00352755·18 enrolled
Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients
Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT05321329·28 enrolled
Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei
Unknown status·MMaimónides Biomedical Research Institute of Córdoba·Phase 1·NCT04982146·10 enrolled
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
Unknown status·MMucpharm Pty Ltd·Phase 2·NCT03976973·62 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)